Genetic control of NKT cell numbers

Immunology and Cell Biology

Volumn 82, Issue 3, 2004, Pages 276-284

  Jordan, Margaret A ^a   Fletcher, Julie ^a   Baxter, Alan G ^a  

^a JAMES COOK UNIVERSITY   (Australia)

Author keywords

Autoimmunity; Diabetes; Disease susceptibility; Genes; Linkage analysis; Lupus; NK cells

Indexed keywords

CD1 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 15; INTERLEUKIN 2; PROTEIN P75; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1;

ALLELE; CELL COUNT; CHROMOSOME 1; GENE; GENE DELETION; GENE IDENTIFICATION; GENE LOCATION; GENE MAPPING; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; IMMUNE RESPONSE; IMMUNOREGULATION; MEF GENE; MOLECULAR DYNAMICS; NATURAL KILLER CELL; NONHUMAN; NOTCH1 GENE; RAG GENE; REVIEW; SCID GENE; VAV1 GENE;

AUTOIMMUNE DISEASES; CELL COUNT; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 18; CHROMOSOMES, HUMAN, PAIR 2; COMMUNICABLE DISEASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 3042805384     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0818-9641.2004.01264.x     Document Type: Review

References (116)

1. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol. Today 2000; 21: 573-83.
2. Capone M, Cantarella D, Schumann J et al. Human invariant V alpha 24-J alpha Q TCR supports the development of CD1d-dependent NK1.1+ and NK1.1- T cells in transgenic mice. J. Immunol. 2003; 170: 2390-98.
3. Emoto M, Kaufmann SH. Liver NKT cells: an account of heterogeneity. Trends Immunol. 2003; 24: 364-9.
4. Grubor-Bauk B, Simmons A, Mayrhofer G, Speck PG. Impaired clearance of Herpes simplex virus type 1 from mice lacking CD1d or NKT cells expressing the semivariant Vα 14-Jα 281 TCR. J. Immunol. 2003; 170: 1430-34.
5. Exley MA, Bigley NJ, Cheng O et al. Innate immune response to encephalomyocarditis virus infection mediated by CD1d. Immunology 2003; 110: 519-26.
6. Ashkar AA, Rosenthal KL. Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection. J. Virol. 2003; 77: 10 168-71.
7. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J. Exp. Med. 2000; 192: 921-30.
8. Barton JL, Gardiner L, Nishimura S, Shinkai K, Locksley R, Ganem D. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity 2002; 16: 583-94.
9. van Dommelen SL, Tabarias HA, Smyth MJ, Degli-Esposti MA. Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells. J. Virol. 2003; 77: 1877-84.
10. Lucas M, Gadola S, Meier U et al. Frequency and phenotype of circulating Valpha24/Vbeta11 double-positive natural killer T cells during hepatitis C virus infection. J. Virol. 2003; 77: 2251-7.
11. Kawakami K, Yamamoto N, Kinjo Y et al. Critical role of Valpha14+ natural killer T cells in the innate phase of host protection against Streptococcus pneumoniae infection. Eur. J. Immunol. 2003; 33: 3322-30.
12. Szalay G, Ladel CH, Blum C, Brossay L, Kronenberg M, Kaufmann SH. Cutting edge: anti-CD1 monoclonal antibody treatment reverses the production patterns of TGF-beta 2 and Th1 cytokines and ameliorates listeriosis in mice. J. Immunol. 1999; 162: 6955-8.
13. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat. Immunol. 2003; 4: 1230-37.
14. + natural killer T cells by α-galactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans. Infect. Immun. 2001; 69: 213-20.
15. Kawakami K, Kinjo Y, Uezu K et al. Monocyte chemoattractant protein-1-dependent increase of V alpha 14 NKT cells in lungs and their roles in Th1 response and host defense in cryptococcal infection. J. Immunol. 2001; 167: 6525-32.
16. Hansen DS, Siomos MA, De Koning-Ward T, Buckingham L, Crabb BS, Schofield L. CD1d-restricted NKT cells contribute to malarial splenomegaly and enhance parasite-specific antibody responses. Eur. J. Immunol. 2003; 33: 2588-98.
17. Gonazlez-Aseguinolaza G, de Oliveira C, Tomaska T et al. alpha-galatosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria. Proc. Natl Acad. Sci. USA 2000; 97: 8461-6.
18. Ishikawa H, Hisaeda H, Taniguchi M et al. CD4(+) v(alpha) 14 NKT cells play a crucial role in an early stage of protective immunity against infection with Leishmania major. Int. Immunol. 2000; 12: 1267-74.
19. Duthie MS, Wleklinski-Lee M, Smith S, Nakayama T, Taniguchi M, Kahn SJ. During Trypanosoma cruzi infection CD1d-restricted NK T cells limit parasitemia and augment the antibody response to a glycophosphoinositol-modified surface protein. Infect. Immun. 2002; 70: 36-48.
20. Cui J, Shin T, Kawano T et al. Requirement for vα 14 NKT cells in IL-12-mediated rejection of tumors. Science 1997; 278: 1626-9.
21. Smyth MJ, Thia KYT, Street SEA et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 2000; 191: 661-8.
22. Smyth MJ, Taniguchi M, Street SAE et al. The anti-tumor activity of IL-12: Mechanisms of innate immunity that are model and dose dependent. J. Immunol. 2000; 165: 2665-70.
23. Kawano T, Cui J, Koezuka Y et al. Natural killer-like non-specific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc. Natl Acad. Sci. USA 1998; 95: 5690-93.
24. Takeda K, Seki S, Ogasawara K et al. 1+ CD4+ alpha beta T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. J. Immunol. 1996; 156: 3366-73.
25. Smyth MJ, Crowe NY, Hayakawa Y, Takeda K, Yagita H, Godfrey DI. NKT cells - conductors of tumor immunity? Curr. Opin. Immunol. 2002; 14: 165-71.
26. Seino KI, Fukao K, Muramoto K et al. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc. Natl Acad. Sci. USA 2001; 98: 2577-81.
27. Sonoda K-H, Taniguchi M, Stein-Streilein J. Long-term survival of corneal allografts is dependent on intact CD1d-reactive NKT cells. J. Immunol. 2002; 168: 2028-34.
28. Hammond KJ, Poulton LD, Palmisano LJ, Silveira PA, Godfrey DI, Baxter AG. Alpha/beta-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J. Exp. Med. 1998; 187: 1047-56.
29. Singh AK, Wilson MT, Hong S et al. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 2001; 194: 1801-11.
30. Huber S, Sartini D, Exley M. Role of CD1d in Coxsackievirus B3-induced myocarditis. J. Immunol. 2003; 170: 3147-53.
31. Jahng AW, Maricic I, Pedersen B et al. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med. 2001; 194: 1789-99.
32. Fritz RB, Zhao ML. Regulation of experimental autoimmune encephalomyelitis in the C57BL/6J mouse by NK1.1+, DX5+, alpha beta+ T cells. J. Immunol. 2001; 166: 4209-15.
33. Zeng D, Liu Y, Sidobre S, Kronenberg M, Strober S. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J. Clin. Invest. 2003; 12: 1211-22.
34. Yang JQ, Saxena V, Xu H, Van Kaer L, Wang CR, Singh RR. Repeated alpha-galactosylceramide administration results in expansion of NK T cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice. J. Immunol. 2003; 171: 4439-46.
35. Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev. Immunol. 2002; 2: 557-68.
36. Bendelac A. Mouse NK1+ T cells. Curr. Opin. Immunol. 1995; 7: 367-74.
37. Kawano T, Cui J, Koezuka Y et al. CD1d-restricted and TCR-mediated activation of Valpha14 NKT cells by glycosylceramides. Science 1997; 278: 1626-9.
38. Burdin N, Brossay L, Koezuka Y et al. Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes. J. Immunol. 1998; 161: 3271-81.
39. Schofield L, McConville MJ, Hansen D et al. CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. Science 1999; 283: 225-9.
40. Pellicci DG, Hammond KJL, Uldrich AP, Baxter AG, Smyth MJ, Godfrey DI. A natural killer T (NKT) cell developmental pathway involving a thymus-dependent NK1.1-CD4+ CD1d-dependent precursor stage. J. Exp. Med. 2002; 195: 835-44.
41. Pellicci DG, Uldrich AP, Kyparissoudis K et al. Intrathymic NKT cell development is blocked by the presence of α-galactosylceramide. Eur. J. Immunol. 2003; 33: 1816-23.
42. Gombert JM, Herbelin A, Tancrede-Bohin E, Dy M, Carnaud C, Bach JF. Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. Eur. J. Immunol. 1996; 26: 2989-98.
43. Baxter AG, Kinder SJ, Hammond KJ, Scollay R, Godfrey DI. Association between alphabetaTCR+CD4-CD8- T-cell deficiency and IDDM in NOD/Lt mice. Diabetes 1997; 46: 572-82.
44. Godfrey DI, Kinder SJ, Silveira PA, Baxter AG. Flow cytometric study of T cell development in NOD mice reveals a deficiency in alphabetaTCR+CDR-CD8- thymocytes. J. Autoimmun. 1997; 10: 279-85.
45. Hammond KJ, Pellicci DG, Poulton LD et al. CD1d-restricted NKT cells: an interstrain comparison. J. Immunol. 2001; 167: 1164-73.
46. Poulton LD, Smyth MJ, Hawke CG et al. Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice. Int. Immunol. 2001; 13: 887-96.
47. Laloux V, Beaudoin L, Jeske D, Carnaud C, Lehuen A. NK T cell-induced protection against diabetes in V alpha 14-J alpha 281 transgenic nonobese diabetic mice is associated with a Th2 shift circumscribed regionally to the islets and functionally to islet autoantigen. J. Immunol. 2001; 166: 3749-56.
48. Lehuen A, Lantz O, Beaudoin L et al. Overexpression of natural killer T cells protects Valpha14-Jalpha281 transgenic nonobese diabetic mice against diabetes. J. Exp. Med. 1998; 188: 1831-9.
49. Hong S, Wilson MT, Serizawa I et al. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. 2001; 7: 1052-6.
50. Mars LT, Laloux V, Goude K et al. Cutting edge: V alpha 14-J alpha 281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice. J. Immunol. 2002; 168: 6007-11.
51. Teige A, Teige I, Lavasani S et al. CD1-dependent regulation of chronic central nervous system inflammation in experimental autoimmune encephalomyelitis. J. Immunol. 2004; 172: 186-94.
52. +B cells at the onset of autoimmune disease in (NZBxNZW)F1 mice. Eur. J. Immunol. 2002; 32: 2551-61.
53. Matsuki N, Stanic AK, Embers ME, Van Kaer L, Morel L, Joyce S. Genetic dissection of V alpha 14J alpha 18 natural T cell number and function in autoimmune-prone mice. J. Immunol. 2003; 170: 5429-37.
54. Baxter AG, Cooke A. Peptide therapy in diabetes. Lancet 1994; 343: 1169.
55. Baxter AG, Horsfall AC, Healey D et al. Mycobacteria precipitate SLE-like syndrome in diabetes prone NOD mice. Immunology 1994; 83: 227-31.
56. Horsfall AC, Howson R, Silveira P, Williams DG, Baxter AG. Characterisation and specificity of B cell responses in lupus induced by M. bovis in NOD/Lt mice. Immunology 1998; 95: 8-17.
57. Hawke CG, Painter DM, Kirwan PD, van Driel IR, Baxter AG. Mycobacteria, an environmental enhancer of lupus nephritis in a mouse model of systemic lupus erythematosus. Immunology 2003; 208: 70-78.
58. Smyth MJ, Godfrey DI. NKT cells and tumour immunity - a double edged sword. Nat. Immunol. 2000; 1: 459-60.
59. DiSanto JP, Muller W, Guy-Grand D, Fischer A, Rajewsky K. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc. Natl Acad. Sci. USA 1995; 92: 377-81.
60. Lantz O, Sharara LI, Tilloy F, Andresson A, DiSanto J. Lineage relationships and differentiation of natural killer (NK) T cells: Intrathymic selection and interleukin (IL)-4 production in the absence of NKR-P1 and Ly49 molecules. J. Exp. Med. 1997; 185: 1395-401.
61. Peschon JJ, Morrissey PJ, Grabstein KH et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J. Exp. Med. 1994; 180: 1955-60.
62. He YW, Malek TR. Interleukin-7 receptor alpha is essential for the development of gamma delta + T cells, but not natural killer cells. J. Exp. Med. 1996; 184: 289-93.
63. Dorschkind K. The severe combined immunodeficient (SCID) mouse. In: Rihova B, Vetvicka V (eds). Immunologic Disorders in Mice. Boca Raton, FL: CRC Press, 1991; 1-21.
64. Radkte F, Wilson A, Stark G et al. Deficient T cell fate specification in mice with an induced inactivation of Notch I. Immunity 1999; 10: 547-58.
65. Bustelo XR. Regulatory and signaling properties of the Vav family. Mol. Cell Biol. 2000; 20: 1461-77.
66. Turner M, Mee PJ, Walters AE et al. A requirement for the Rho-family GTP exchange factor Vav in positive and negative selection of thymocytes. Immunity 1997; 7: 451-60.
67. Kong YY, Fischer KD, Bachmann MF et al. Vav regulates peptide-specific apoptosis in thymocytes. J. Exp. Med. 1998; 188: 2099-111.
68. Fischer KD, Zmuldzinas A, Gardner S, Barbacid M, Bernstein A, Guidos C. Defective T-cell receptor signalling and positive selection of Vav-deficient CD4+ CD8+ thymocytes. Nature 1995; 374: 474-7.
69. Fischer KD, Kong YY, Nishina H et al. Vav is a regulator of cytoskeletal reorganization mediated by the T-cell receptor. Curr. Biol. 1998; 8: 554-62.
70. Holsinger LJ, Graef IA, Swat W et al. Defects in actin-cap formation in Vav-deficient mice implicate an actin requirement for lymphocyte signal transduction. Curr. Biol. 1998; 8: 563-72.
71. Chan G, Hanke T, Fischer KD. Vav-1 regulates NK T cell development and NK cell cytotoxicity. Eur. J. Immunol. 2001; 31: 2403-10.
72. Seth A, Ascione R, Fisher RJ, Mavrothalassitis GJ, Bhat NK, Papas TS. The Ets gene family. Cell Growth Differ. 1992; 3: 327-34.
73. Barton K, Muthusamy N, Fischer C et al. The Ets-1 transcription factor is required for the development of natural killer cells in mice. Immunity 1998; 9: 555-63.
74. Walunas TL, Wang B, Wang CR, Leiden JM. Cutting edge: the Ets1 transcription factor is required for the development of NK T cells in mice. J. Immunol. 2000; 164: 2857-60.
75. Lacorazza HD, Miyazaki Y, Di Cristofano A et al. The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. Immunity 2002; 17: 437-49.
76. Smyth MJ, Johnstone RW, Cretney E et al. Multiple deficiencies underlie NK cell inactivity in lymphotoxin-alpha gene-targeted mice. J. Immunol. 1999; 163: 1350-53.
77. Elewaut D, Brossay L, Santee SM et al. Membrane lymphotoxin is required for the development of different subpopulations of NK T cells. J. Immunol. 2000; 165: 671-9.
78. Lodolce JP, Boone DL, Chai S et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998; 9: 669-76.
79. Suzuki H, Kundig TM, Furlonger C et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 1995; 268: 1472-6.
80. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Sadlack B, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993; 75: 253-61.
81. Kennedy MK, Glaccum M, Brown SN et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 2000; 191: 771-80.
82. Ohteki T, Maki C, Koyasu S. Overexpression of Bcl-2 differentially restores development of thymus-derived CD4-8+ T cells and intestinal intraepithelial T cells in IFN-regulatory factor-1-deficient mice. J. Immunol. 2001; 166: 6509-13.
83. Ohteki T, Yoshida H, Matsuyama T, Duncan GS, Mak TW, Ohashi PS. The transcription factor interferon regulatory factor 1 (IRF-1) is important during the maturation of natural killer 1.1+ T cell receptor-alpha/beta+ (NK1+T) cells, natural killer cells, and intestinal intraepithelial T cells. J. Exp. Med. 1998; 187: 967-72.
84. Cortes M, Wong E, Koipally J, Georgopoulos K. Control of lymphocyte development by the Ikaros gene family. Curr. Opin. Immunol. 1999; 11: 167-71.
85. Wang JH, Nichogiannopoulou A, Wu L et al. Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. Immunity 1996; 5: 537-49.
86. Georgopoulos K, Bigby M, Wang JH et al. The Ikaros gene is required for the development of all lymphoid lineages. Cell 1994; 79: 143-56.
87. Chen YH, Chiu NM, Mandal M, Wang N, Wang CR. Impaired NK1+ T cell development and early IL-4 production in CD1-deficient mice. Immunity 1997; 4: 459-67.
88. Ohteki T, MacDonald HR. Major histocompatibility complex class I related molecules control the development of CD4+8-and CD4-8- subsets of natural killer 1.1+ T cell receptor-alpha/beta+ cells in the liver of mice. J. Exp. Med. 1994; 180: 699-704.
89. Elewaut D, Lawton AP, Nagarajan NA et al. The adaptor protein AP-3 is required for CD1d-mediated antigen presentation of glycosphingolipids and development of Valpha14i NKT cells. J. Exp. Med. 2003; 198: 1133-46.
90. Honey K, Benlagha K, Beers C et al. Thymocyte expression of cathepsin L is essential for NKT cell development. Nat. Immunol. 2002; 3: 1069-74.
91. Riese RJ, Shi GP, Villadangos J et al. Regulation of CD1 function and NK1.1(+) T cell selection and maturation by cathepsin S. Immunity 2001; 15: 909-19.
92. Honey K, Rudensky AY. Lysosomal cysteine proteases regulate antigen presentation. Nat. Rev. Immunol. 2003; 3: 472-82.
93. Sato H, Nakayama T, Tanaka Y et al. Induction of differentiation of pre-NKT cells to mature Valpha14 NKT cells by granulocyte/ macrophage colony-stimulating factor. Proc. Natl Acad. Sci. USA 1999; 96: 7439-44.
94. Elewaut D, Shaikh RB, Hammond KJ et al. NIK-dependent RelB activation defines a unique signaling pathway for the development of V alpha 14i NKT cells. J. Exp. Med. 2003; 197: 1623-33.
95. Caamaño J, Alexander J, Craig L, Bravo R, Hunter CA. The NF-B family member RelB is required for innate and adaptive immunity to Toxoplasma gondii. J. Immunol. 1999; 163: 4453-61.
96. DeKoning J, DiMolfetto L, Reilly C, Wei Q, Havran WL, Lo D. Thymic cortical epithelium is sufficient for the development of mature T cells in RelB-deficient mice. J. Immunol. 1997; 158: 2558-66.
97. Williams KL, Nanda I, Lyons GE et al. Characterisation of murine BATF: a negative regulator of activator protein-1 activity in the thymus. Eur. J. Immunol. 2001; 31: 1620-27.
98. Williams KL, Zullo AJ, Kaplan MH, Brutkiewicz RR, Deppmann CD, Vinson C, Taparowsky EJ. BATF transgenic mice reveal a role for activator protein-1 in NKT cell development. J. Immunol. 2003; 170: 2417-26.
99. Eberl G, Lowin-Kropf B, MacDonald HR. Cutting edge: NKT cell development is selectively impaired in Fyn-deficient mice. J. Immunol. 1999; 163: 4091-4.
100. Gadue P, Morton N, Stein PL. The Src family tyrosine kinase Fyn regulates natural killer T cell development. J. Exp. Med. 1999; 190: 1189-96.
101. Gadue P, Stein PL. NK T cell precursors exhibit differential cytokine regulation and require Itk for efficient maturation. J. Immunol. 2002; 169: 2397-406.
102. Ohteki T, Maki C, Koyasu S, Mak TW, Ohashi PS. Cutting edge: LFA-1 is required for liver NK1.1+TCR alpha beta+ cell development: evidence that liver NK1.1+TCR alpha beta+ cells originate from multiple pathways. J. Immunol. 1999; 162: 3753-6.
103. Emoto M, Mittrucker HW, Schmits R, Mak TW, Kaufmann SH. Critical role of leukocyte function-associated antigen-1 in liver accumulation of CD4+NKT cells. J. Immunol. 1999; 162: 5094-8.
104. Carnaud C, Gombert J-M, Donnars O, Garchon H-J, Herbelin A. Protection against diabetes and improved NK/NKT cell performance in NOD.NK1.1 mice congenic at the NK complex. J. Immunol. 2001; 166: 2404-11.
105. Rogner UC, Boitard C, Morin J, Melanitou E, Avner P. Three loci on mouse chromosome 6 influence onset and final incidence of type I diabetes in NOD.C3H congenic strains. Genomics 2001; 74: 163-71.
106. Lord CJ, Howlett S, Lyons PA, Peterson LB, Wicker LS, Todd JA. The murine type 1 diabetes loci, Idd1, Idd3, Idd5, Idd9, and Idd17/10/18, do not control thymic CD4-CD8-/TCRalphabeta+ deficiency in the nonobese diabetic mouse. Mamm. Genome 2001; 12: 175-6.
107. Zhang F, Liang Z, Matsuki N et al. A murine locus on chromosome 18 controls NKT cell homeostasis and Th cell differentiation. J. Immunol. 2003; 171: 4613-20.
108. Esteban LM, Tsoutsman T, Jordan MA et al. Genetic control of NKT cell numbers maps to major diabetes and lupus loci. J. Immunol. 2003; 171: 2873-8.
109. Jordan MA, Silveira PA, Shepherd DP et al. Linkage analysis of systemic lupus erythematosus induced in diabetes-prone non-obese diabetic mice by Mycobacterium bovis. J. Immunol. 2000; 165: 1673-84.
110. Morel L, Mohan C, Yu Y et al. Functional dissection of systemic lupus erythematosus using congenic mouse strains. J. Immunol. 1997; 158: 6019-28.
111. Drake CG, Babcock SK, Palmer E, Kotzin BL. Genetic analysis of the NZB contribution to lupus-like autoimmune disease in (NZB x NZW)F1 mice. Proc. Natl Acad. Sci. USA 1994; 91: 4062-6.
112. Kono DH, Burlingame RW, Owens DG et al. Lupus susceptibility loci in New Zealand mice. Proc. Natl Acad. Sci. USA 1994; 91: 10 168-72.
113. Moser KL, Neas BR, Salmon JE et al. Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees. Proc. Natl Acad. Sci. USA 1998; 95: 14 869-74.
114. Moser KL, Gray-McGuire C, Kelly J et al. Confirmation of genetic linkage between human systemic lupus erythematosus and chromosome 1q41. Arthritis Rheum. 1999; 42: 1902-7.
115. Gaffney PM, Kearns GM, Shark KB et al. A genome-wide search for susceptibility genes in human systemic lupus erythematosus sib-pair families. Proc. Natl Acad. Sci. USA 1998; 95: 14 875-9.
116. Hamilton-Williams EE, Serreze DV, Charlton B et al. Transgenic rescue implicates beta2-microglobulin as a diabetes susceptibility gene in nonobese diabetic (NOD) mice. Proc. Natl Acad. Sci. USA 2001; 98: 11 533-8.